Guillain-Barré syndrome laboratory tests

Revision as of 15:40, 18 December 2018 by Fahimeh Shojaei (talk | contribs)
Jump to navigation Jump to search

Guillain-Barré syndrome Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Guillain-Barré syndrome from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural history, Complications, and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Guillain-Barré syndrome laboratory tests On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Guillain-Barré syndrome laboratory tests

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Guillain-Barré syndrome laboratory tests

CDC on Guillain-Barré syndrome laboratory tests

Guillain-Barré syndrome laboratory tests in the news

Blogs on Guillain-Barré syndrome laboratory tests

Directions to Hospitals Treating Guillain-Barré syndrome

Risk calculators and risk factors for Guillain-Barré syndrome laboratory tests

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Priyamvada Singh, MBBS [2]

Overview

Laboratory Findings

  • Laboratory findings consistent with the diagnosis of Guillain Barre syndrome include:[1][2][3]
    • Elevated CSF protein level.
    • Normal CSF WBC count.
    • Normal CSF cell count (in some cases there is mildly elevated cell count)

References

  1. Yuki N, Hartung HP (June 2012). "Guillain-Barré syndrome". N. Engl. J. Med. 366 (24): 2294–304. doi:10.1056/NEJMra1114525. PMID 22694000.
  2. Nishimoto Y, Odaka M, Hirata K, Yuki N (March 2004). "Usefulness of anti-GQ1b IgG antibody testing in Fisher syndrome compared with cerebrospinal fluid examination". J. Neuroimmunol. 148 (1–2): 200–5. doi:10.1016/j.jneuroim.2003.11.017. PMID 14975602.
  3. Fokke C, van den Berg B, Drenthen J, Walgaard C, van Doorn PA, Jacobs BC (January 2014). "Diagnosis of Guillain-Barré syndrome and validation of Brighton criteria". Brain. 137 (Pt 1): 33–43. doi:10.1093/brain/awt285. PMID 24163275.

Template:WH Template:WS